nemvaleukin alfa
nemvaleukin alfa: developed by 1 company · 2 clinical trials tracked.
nemvaleukin alfa evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could nemvaleukin alfa → MURA affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Mural Oncology plc (MURA) Cutaneous Melanoma | Phase 3 |
Clinical Trials (2)
A Phase 2, Open-Label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6
Primary endpoint: Centrally-assessed overall response rate (ORR) (Cohort 1 and 2)
A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-1
Primary endpoint: Part A: Number of Participants With Dose-limiting Toxicities (DLTs) Based on Common Terminology Criteria for Adverse Events (CTCAE)
Frequently asked questions
Who is developing nemvaleukin alfa?
nemvaleukin alfa is being developed by Mural Oncology plc.
How many clinical trials involve nemvaleukin alfa?
BioSniper tracks 2 clinical trials involving nemvaleukin alfa.